Cyclo-Proginova 21 tablets

Trade name:

Cyclo-Progynova

Compound:

Each tablet contains:

norgestrel 0.5 mg

estradiol valerate 2 mg

Auxiliary components:

lactose monohydrate, corn starch, povidone, talc, magnesium stearate, sucrose, povidone, macrogol 6000, calcium carbonate, talc, glycerol 85%, mountain glycol wax, titanium dioxide (E171), iron dye yellow oxide (E172), iron oxide dye red (E172).

Properties:

Combined hormonal drug containing estrogen and progestogen.

Estradiol valerate is an estrogen that is converted to natural 17β-estradiol in the human body.

Norgestrel is a derivative of progesterone.

The addition of norgestrel within 10 days of each cycle prevents the development of hyperplasia and endometrial cancer.

Due to the composition and cyclical regimen of this combination (taking only estrogen for 11 days, then taking a combination of estrogen and progestogen for 10 days, and finally a 7-day break), in women with an unremoved uterus, with regular use of the drug, a menstrual cycle is established.

Against the background of taking this combination, there is no suppression of ovulation, and the production of hormones in the body itself practically does not change.

Estradiol compensates for the deficiency of estrogen in the female body after menopause and provides effective treatment of psycho-emotional and vegetative menopausal symptoms (such as “hot flashes”, increased sweating, sleep disturbance, increased nervous excitability, irritability, palpitations, cardialgia, dizziness, headache, decreased libido, muscle and joint pain); involution of the skin and mucous membranes, especially the mucous membranes of the genitourinary system (urinary incontinence, dryness and irritation of the vaginal mucosa, pain during intercourse).

Indications:

Hormone replacement therapy for menopausal disorders, involutional changes in the skin and urinary tract and genital tract, depressive conditions in the menopause, as well as symptoms of estrogen deficiency due to natural menopause or hypogonadism, sterilization or primary ovarian dysfunction in women with an unremoved uterus; prevention of postmenopausal osteoporosis; normalization of irregular menstrual cycles; treatment of primary or secondary amenorrhea.

Dosage and administration:

The optimal dosing regimen is determined by the doctor. Compliance of the dosage form of a particular drug with indications for use and dosing regimen should be strictly observed.

Taken inside.

The scheme of application depends on the indications and the state of the menstrual cycle.

Contraindications:

Hypersensitivity to the components of the combination; pregnancy, breastfeeding period; vaginal bleeding of unknown origin; a confirmed or suspected diagnosis of breast cancer; a confirmed or suspected diagnosis of hormone-dependent precancerous disease or hormone-dependent malignant tumors; liver tumors at present or in history (benign or malignant); severe liver disease; acute arterial thrombosis or thromboembolism (such as myocardial infarction, stroke); deep vein thrombosis in the acute stage, thromboembolism at present or in history; severe hypertriglyceridemia.

Precautionary measures:

This combination is not used for contraception.

In the presence or worsening of any of the conditions or risk factors listed below, before starting or continuing HRT, the individual risk-benefit ratio of treatment should be assessed.

In a number of controlled randomized, as well as epidemiological studies, an increased relative risk of developing venous thromboembolism (VTE) against the background of HRT, i.e. deep vein thrombosis or pulmonary embolism. Therefore, when prescribing HRT to women with risk factors for VTE, the risk-benefit ratio of treatment should be carefully weighed and discussed with the patient.

Side effects:

From the reproductive system and mammary glands: changes in the frequency and intensity of uterine bleeding, breakthrough bleeding.

From the digestive system: dyspepsia, bloating, nausea, vomiting, abdominal pain, relapse of cholestatic jaundice.

From the skin and subcutaneous tissue: skin rash, pruritus, chloasma, erythema nodosum.

From the nervous system: headache, migraine, dizziness, anxiety or depressive symptoms, increased fatigue.

From the side of the cardiovascular system: tachycardia, increased blood pressure.

From the blood coagulation system: venous thrombosis and thromboembolism.

Other: swelling, muscle cramps, changes in body weight, changes in libido.

Storage method:

Store at a temperature not exceeding 30 degrees.

Package:

The carton contains a blister of 21 tablets.